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Fimea - the Finnish Medicines Agency - starts its work
Marja-Liisa Partanen
Director General
National Agency for Medicines (NAM)
Editorial
Fimea is a key agency of the Ministry of Social Af-
fairs and Health, promoting the health and safety of
the population through the regulation of drugs and
blood and tissue products, and by developing the
pharmaceutical sector. The agency’s responsibilities
lie in the areas of marketing authorisation and regu-
lation, and research and development. A legislative
basis has been established for the new Finnish Medi-
cines Agency, Fimea. The Parliament ratified the Act
on the Finnish Medicines Agency on 16.6.2009, and
a decree based on this Act was issued on 13.8.2009.
Future challenges facing the pharmaceutical sec-
tor include an ageing population, the increasing use
of medicines, ever more complex medical treatments,
and growing cost pressures in the social and health-
care services system. Meeting these challenges is one
of the aims of the reorganisation of the administra-
tion of pharmaceutical services, which is based on
the principles of the Social and Healthcare Strategies
2015 of the Ministry of Social Affairs and Health.
The legislation provides a basic framework, but will
not solve everything. The organisational structure of
the agency, its management system and strategic
starting points and choices will create a basis upon
which the newly-established agency can work to
meet the challenges facing it. 
What should the characteristics and working
principles of the new agency be? It should be a total-
ly new actor whose core expertise should be not on-
ly ensuring safe and effective pharmacotherapy, but
also developing the pharmaceutical sector and fur-
thering cooperation, managing information in the
pharmaceutical sector, and using it effectively. The
Finnish Medicines Agency is an independent, inter-
national force that is prepared to commit to what it
believes in. It will do everything in its power to pro-
mote the safety of drugs and pharmacotherapy as a
single entity. It safeguards a targeted and effective
chain from the laboratory to the consumer. It is
strategically important that the agency is also pre-
pared to actively predict prevailing trends in the in-
dustry, and developments in its own area of activity.
We must keep at the forefront of developments
rather than remain at a standstill, or even go into re-
verse. Legislative preparatory documents regarding
this administrative reorganisation – for example the
government proposal relating to the administrative
act on the agency – include a number of sections pro-
viding guidelines for developing the new agency, such
as the following: the aim of the agency should be to
further improve customer service and the effective-
ness of working methods in pre- and post-regulation.
Within the context of the agency’s responsibilities re-
lating to marketing authorisation and regulation in
the pharmaceutical services field, its aims include de-
veloping novel solutions relating to information tech-
nology and administrative organisation, for instance
enabling the use of electronic customer contacts and
automated office administration systems. Aims relat-
ing to restructuring include identifying working
methods and processes that are in need of develop-
ment, and on that basis enhancing their appropriate-
ness for customers in order to generate added value
for interest groups and customers of the agency.
From the point of view of the population, it is
important that the efficacy, safety and quality of
drugs used in Finland are safeguarded by means of
effective drug regulation. From the point of view of
society, it is important that drug regulation guaran-
tees effective and efficient medical treatment, to al-
low people to recover quickly from diseases which
reduce their capacity to work, and enable them to
remain working until as late an age as possible. The
principal aim for the agency here is to use its new re-
sponsibilities relating to research and development
to monitor more closely the views of the population
and patients who use medicines in the pharmaceuti-
cal field, within the context of social and health
care. The Finnish Medicines Agency has the oppor-
tunity to generate research data to back up medico-
political decision making. It also has the opportunity
to contribute to slowing the growth of drug costs,
and to generate added value for its interest groups
and customers in accordance with its social aims.
We have the means at our disposal, and are now
fine-tuning the Fimea engine together, to enable us
to respond to future challenges.
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An increase in subliminal drug advertising is a
concern for the authorities
TV soaps and social media are attracting drugs distributors
Kristiina Pellas
Senior Pharmaceutical Inspector
National Agency for Medicines (NAM)
Paavo Autere
Lawyer 
National Agency for Medicines (NAM)
Erkki Palva
Professor, Head of Department 
National Agency for Medicines (NAM)
In the summer of 2009 NAM
found it necessary to examine the
type of information currently
available to members of the public
who perform an internet search
on the trade name of a specific
prescription drug. A survey was
carried out whereby statistical da-
ta were gathered on the basis of
the Google hits obtained when the
names of one hundred new pre-
scription drugs were entered. The
drugs’ trade names were entered
and the hits obtained were classi-
fied, and the sequence in which
they appeared recorded (table).
The survey considered Finnish
search results only.
Certain websites appeared
very frequently among the search
results. Among the top hits were
usually the websites of the Euro-
pean Medicines Agency (EMEA)
Over the past year, from 2008 to 2009, NAM was forced to intervene on as many as ten separate oc-
casions in cases where information about prescription drugs had been disseminated to the public via
various media. Increasingly, pharmaceutical companies are placing information about prescription
drugs in real-life contexts, where they occupy a grey area between subliminal advertising and legiti-
mate marketing. Companies are well aware that prescription drugs cannot be marketed directly to the
public. In order for drug marketing to be lawful, it must be neither misleading nor inappropriate. Com-
panies looking to grow by increasing their visibility on the market are nevertheless keen to identify
new ways of distributing information about drugs. Today’s communication and marketing channels
give pharmaceutical companies the opportunity to employ new ways of working. Social networking
websites attract companies wishing to make their information about prescription drugs more widely
available, for example by placing references to the drug’s trade name online. The most popular new
media include the website YouTube and Finnish TV soaps and radio programmes. Information is dis-
seminated inconspicuously and without the audience having requested it, either via the media or in
locations encountered by people in their everyday lives. 
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Table. When an internet search was performed for the names of one hundred differ-
ent medicinal products, the 100 pages of search  results contained links to 948 differ-
ent websites in total. The combined hits obtained by entering one hundred product
names were as follows:
On 100 pages of hits 948 hits in total
80 % Lääkeinfo.fi web pages 96 hits from 100 searches
76 % EMEA web pages 136 hits
66 % Helsinki University Pharmacy web pages 117 hits
66 % Terveysportti 102 hits
53 % Tohtori.fi 65 hits
53 % Finnish pharmaceutical company web pages 84 hits
48 % Web pages related to therapeutic indication of drug  68 hits
47 % European Commission web pages 74 hits
43 % NAM web pages 62 hits
31 % Suomi24.fi 48 hits
15 % The Pharmaceutical Pricing Board web pages 15 hits
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or the National Agency for Medi-
cines (NAM). The official sum-
maries of product characteristics
(SPC), package information
leaflets (PL) approved by the au-
thorities, or evaluation reports
(EPAR) are published on these
websites for the various drugs.
The EMEA website gives the
SPCs and PLs of products which
have been granted marketing au-
thorisation via the centralised
procedure, while the NAM web-
site gives details of those prod-
ucts with marketing authorisa-
tion obtained via other proce-
dures. The next most common
hits were from the pharmaceuti-
cal companies’ own websites,
press releases, and Finnish
healthcare or medical sector por-
tals, particularly the Terveysport-
ti website (maintained by Duode-
cim) and the sites tohtori.fi and
verkkoklinikka.fi from Coronar-
ia. Search results also often in-
cluded the Helsinki University
Pharmacy website. Other search
results included, for example,
web pages named after specific
therapies and sponsored by phar-
maceutical companies, and the
websites of patient associations.
Regarding product placement
and subliminal advertising
Product placement has become
an increasingly popular form of
marketing. When applied to
drugs, product placement is
where a prescription drug ap-
pears in a context in a radio or
television programme, or on the
website YouTube, or in a news-
paper article. People will not nec-
essarily see this as sales promo-
tion, but ultimately it is. Product
placement raises awareness of a
certain medicinal product and
conveys a positive impression of
that product. In the most glaring
cases, the product will be men-
tioned by its trade name, and in
some cases its name and packag-
ing will appear together in the
same image. Occasionally, only
the company name and logo will
be apparent. Product placement
provides the viewer, listener or
reader with information about a
drug or a pharmaceutical compa-
ny without his or her choosing to
receive that information.
The National Agency for
Medicines monitors the appropri-
ateness of drug marketing. This
monitoring work is managed ac-
cording to the stipulations of the
Medicines Act and Decree. Prod-
uct placement of most other
products in Finland apart from
medicinal products is monitored
by the Finnish Consumer Agency.
On its website, the Consumer
Agency provides the following
guidelines for companies regard-
ing the legal principles relevant
to product placement: Through
product placement of products,
services, trade names etc. in vari-
ous programmes, manufactures 
Regulation of drug marketing
• According to Section 91a of the Medicines Act (395/ 1987), pre-
scription drugs may not be marketed to the general population. In
order to meet freedom of speech requirements, neutral writing
which is not aimed at promoting sales is permitted.
• Again according to Section 91a, drug marketing must not encou-
rage people to use drugs in cases where they are not strictly necessa-
ry, must not give a misleading or exaggerated impression regarding
the concentration of the product, its origin or its medical significan-
ce, and generally must be appropriate. In short, drug marketing
must not be misleading.
• According to Section 25 of the Medicines Decree (693/ 1987),
drug marketing includes all measures relating to communication and
order procurement, with the aim of promoting the prescription,
supply, purchase or consumption of drugs. 
• Freedom of speech requirements also apply to communications re-
lating to diseases, symptoms, and alternative forms of treatment.
However, if a communication of this kind aims to promote sales of
one or more medicinal products, then it is considered marketing. It
is commonly considered that communications made by the pharma-
ceutical industry in connection with health issues must be balanced
and objective, and indeed the National Agency for Medicines ex-
pects this. Information provided about various therapies must be
balanced and, if reference is made to a medicinal product, all pro-
ducts on the market must be mentioned on equal terms. Communi-
cations regarding health issues where only one product is available
for the prophylaxis of a certain disease are not acceptable. In that
case, the communications would always be considered marketing.
and distributors of products and-
service providers usually intend
to increase sales of their products
by boosting their visibility, i.e. it
is usually done intentionally, for
advertising purposes. Consumers
always have the right to know
when they are being influenced
in their perception of a product. 
What type of information can
be accessed by the public by
running an internet search on
the name of a drug?
The purpose of the survey was to
establish the type of information
that people can access about a
prescription drug when they per-
form an internet search on a
product name. A table was com-
piled of the search results ob-
tained when the name of a new
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medicinal product was entered in
a search engine, and the data ob-
tained were analysed. The aim
was to build up a general picture
of the information available, and
to see whether the information
complied with the pharmaceutical
legislation. The website YouTube
was also examined to see whether
drug information came up when
a search was performed for the
various product names. The sur-
vey was carried out as part of
NAM’s work on drug marketing
regulation.
The survey looked primarily
at the information available on-
line about one hundred new
products, all with marketing au-
thorisation, and all available on
the Finnish market. The products
were introduced onto the market
in the years 2006 to 2009, and
generally contained new active
medicinal substances.
Other websites (81 hits) where
names of medicinal products
were mentioned included: www.
paihdelinkki.fi, www.tukiasema.
net, http://kaksplus.fi, www.suo-
mi24.fi, http://sfnet.fi, www.euro-
drugstore.eu, www.mediuutiset. fi,
www.hoitonetti.fi, http://irc-galle-
ria.net/, http://fundconnect.nor-
dea.com, www.hus.fi, www.napsu.
fi, www.terkko.helsinki.fi, www.
positiiviset.fi, http://www.stm.fi/
stm/neuvottelukunnat/hila/etusivu,
www.deski.fi, www.taitomylly.fi,
www.digipaper.fi, www.cancer.fi
and www.vaasankeskussairaala.fi.
Conclusion
In the survey completed on
6.8.2009, whereby the public run
internet searches on the names of
medicinal products, the informa-
tion obtained was found to be
appropriate and in accordance
with the stipulations of the Medi-
cines Act and Decree. Even the
information found on the therapy
groupswebsite was neutral at the
time of the survey. In order for a
piece of information in which the
name of a prescription drug was
mentioned to be deemed appro-
priate, it was essential that all
other forms of therapy and medi-
cinal products were mentioned
with equal emphasis, so that no
product was favoured above any
other. The top hits obtained when
names of prescription drugs were
entered into the search engine
were websites approved by the
authorities, and included pub-
lished summaries of product
characteristics and package
leaflets. Reference to the trade
name of a medicinal product is
not currently a problem in terms
of drug marketing regulations,
and the web pages examined by
NAM were in this regard appro-
priate.
TV, radio and the internet are
the most difficult types of media
to regulate. In future, drug mar-
keting will increasingly be regu-
lated in such a way as to take ac-
count of those media which are
associated with product place-
ment. Drug information provided
via these media is a prime exam-
ple of how some pharmaceutical
companies display poor ethical
standards in their methods of
working. It is inevitable that drug
marketing standards will increas-
ingly be violated in one way or
another in the years to come. The
Finnish Communications Regula-
tory Authority, which regulates
the lawfulness of product place-
ment, has increasingly intervened
in cases associated with drugs
this year.  
Regulating product placement
is the responsibility of a number
of players. The Council for Mass
Media in Finland has on several
occasions demanded that the var-
ious players display ethical re-
sponsibility and respect for the
need for credibility, in order to
get rid of hidden advertising. The
web pages of the Consumer
Agency stress that independence
from commercial interests is con-
sidered essential for maintaining
editorial credibility. The Finnish
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Consumer protection requirements
• Marketing must not be inappropriate or misleading. Marketing
must always be recognisable as marketing. (www.kuluttajavirasto.fi)
• The commercial purpose of marketing activities must be obvious,
and the company responsible for the marketing must be identifiable.
It should always be possible to recognise an advertisement as an ad-
vertisement, commercial messages must not be hidden in other
forms of communication, and the identity of the advertiser must be
clear. Subliminal or hidden advertising is never acceptable.
(www.kuluttajavirasto.fi)
• The stipulations of the Consumer Protection Act apply to all par-
ties, i.e. both the advertiser and advertisement distributor, and the
television company. There are stipulations regarding television bro-
adcasters’ responsibility for the advertising that they disseminate in
the Act on Television and Radio Operations, which also applies re-
strictions to product placement and subliminal advertising.
(www.kuluttajavirasto.fi)
• The responsibilities of the Finnish Communications Regulatory
Authority (FICORA) also include overseeing compliance with regu-
lations regarding subliminal advertising and sponsorship. Subliminal
advertising on television is prohibited, and a sponsor of a television
programme may not influence the content of the sponsored pro-
gramme in such a way that it would violate the responsibilities or
independence of broadcasting of the television operator. 
(www.ficora.fi)
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Communications Regulatory Au-
thority oversees the legality of
product placement in Finland.
Drug marketing posing as
neutral communication has be-
come more common, but this can
be combated jointly by all of the
players in the health sector, in-
cluding the public. Communica-
tions to the public regarding dis-
eases or health issues, without
their having requested it, must
not exclusively market a specific
prescription drug, even indirectly.
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Responsibilities of NAM’s 
Medical Devices department
transferred to Valvira
Ritva Raunio, Deparment secretary
The National Agency for Medi-
cines’ Medical Devices depart-
ment regulates the manufacture
and marketing of medical de-
vices, and promotes the safety
of their use. The responsibilities
of the Medical Devices section
have been the responsibility of
NAM since 1995. 
In 2008, the Ministry of So-
cial Affairs and Health intro-
duced a plan to reform the ad-
ministration of pharmaceutical
services. In the summer of
2009, a new Act was passed re-
garding the Finnish Medicines
Agency, Fimea. Fimea is respon-
sible for promoting the health
and safety of the population by
regulating drugs and blood and
tissue products, and by develop-
ing the pharmaceutical sector.
According to the Act, the re-
sponsibilities of the Medical De-
vices section will be transferred
to the National Supervisory Au-
thority for Welfare and Health
as of 1.11.2009. 
The National Supervisory
Authority for Welfare and
Health (Valvira) is a new cen-
tral body that was formed on
1.1.2009 by a merger between
the National Product Control
Agency for Welfare and Health
(STTV) and the National Au-
thority for Medicolegal Affairs
(TEO). By offering guidance
and supervision, Valvira works
to improve the management of
health risks in the environment,
the standard of legal protection,
and the quality of social welfare
and health services. 
From 1.11.2009, the new
contact details for all issues re-
lating to medical devices will be
as follows:
Valvira 
(National Supervisory Authority
for Welfare and Health)
Lintulahdenkuja 4
PL 210 
FI-00531 Helsinki 
Tel: +358-(0)9-772 920
(exchange)
Fax: +358-(0)9-772 2138
E-mail:
firstname.surname@ valvira.fi
kirjaamo@valvira.fi
www.valvira.fi
News
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